As the tumor microenvironment is thought to play a strong role in driving the progression of WM, we also investigated whether the five patient-matched CD19-CD138- bone marrow cells used as controls in this study were defined by any mutations not present in a cohort of more than 1000 controls previously sequenced by Mayo Clinic for genetic studies of other disease states. The gene discussed is CD19; the disease is neoplasm.